Amylyx Pharmaceuticals Reports Positive Phase 3 Results
CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals, Inc. announced positive topline results from the Phase 3 LUCIDITY clinical trial...
GLP-1
Advertisement
Biomea Fusion Doses First Patient in Obesity OPAL Study
SAN CARLOS, Calif., August 13, 2026 Biomea Fusion, Inc. announced that the first participant has been dosed in a...
Veru Advances PLATEAU Trial with Full Enrollment
Miami, Florida, August 10, 2026 Veru Inc. has announced full enrollment of 239 patients in its Phase 2b PLATEAU...
Entera Bio Advances EB613 Toward Phase 3 Development Following FDA Alignment
TEL AVIV, August 7, 2026 Entera Bio reported its second quarter 2026 financial results and business updates, highlighting regulatory...
Vivani Medical Completes Phase 1 SLIM-1 Dosing of NPM-139 Implant
ALAMEDA, Calif., August 6, 2026 Vivani Medical, Inc. announced the successful full enrollment and initial dosing of all 20...
Advertisements
UCB Reports FINTEPLA Study Showing Sustained LGS Benefits
Atlanta, Georgia, August 5, 2026 UCB has announced the publication of a post hoc analysis in Epilepsia Open demonstrating...
Novo Nordisk Wins Dutch Injunction Over Semaglutide Spray
Bagsværd, Denmark, August 5, 2026 Novo Nordisk has secured a significant legal victory after the District Court of The...
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide for MASH
GAITHERSBURG, Md., Aug. 3, 2026 Altimmune, Inc. has initiated patient enrollment in the global PERFORMA Phase 3 registrational trial...
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Dario Expands Obesity Care with AI-Powered GLP-1 Program
NEW YORK, July 30, 2026 DarioHealth Corp. has unveiled its Integrated GLP-1 Program, a comprehensive healthcare solution that combines...
Advertisement
